Tag: Liver
PIVKA-II-Based Model IDs Liver Cancer Risk in Hep C-Related Cirrhosis
Model accurately predicts hepatocellular carcinoma among patients with HCV-related cirrhosis with SVR to DAAs
Model Can Predict, Stratify Liver Cancer Risk in Noncirrhotic Chronic Hep B
New model exhibited satisfactory discrimination and calibration, with c-statistics of 0.844 and 0.813 in derivation, validation cohorts
Palliative Low-Dose Radiotherapy Improves Pain in Hepatic Cancer
Improvement in hepatic pain seen in 67 percent of patients receiving radiotherapy plus best supportive care
Women With Liver Cancer Less Likely Than Men to Receive Liver Transplant
Furthermore, women are more likely to die waiting for a donor liver than men
Outcomes Similar for Neoadjuvant ICI-Based Therapy, Upfront Surgery for Liver Cancer
Rates of margin-negative resection and recurrence-free survival similar for neoadjuvant immunotherapy, surgery patients
Acceptable Liver Transplant Outcomes Seen After ICI Therapy for Liver Cancer
Age and immune checkpoint inhibitor washout time inversely linked to allograft rejection; survival no different with, without allograft rejection
Blood Test Results Can Enhance Assessment of Cancer Risk
Blood test results enhance assessment of risk for patients presenting with nonspecific abdominal symptoms
Cholesterol Absorption Inhibitors May Cut Risk for Liver Cancer
Results inconsistent for association with bile acid sequestrant use depending on diabetes and liver disease status
Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer
Progression-free survival significantly improved in unresectable hepatocellular carcinoma versus TACE alone
Direct-Acting Antivirals Still Underused in Hep C-Related Liver Cancer
Higher odds of receiving DAA treatment seen for younger age, being seen by a gastroenterologist or infectious disease physician, having cirrhosis
